TY - JOUR AU - Mukherjee, Manali AU - Lim, Hui Fang AU - Thomas, Sruthi AU - Miller, Douglas AU - Kjarsgaard, Melanie AU - Tan, Bruce AU - Sehmi, Roma AU - Khalidi, Nader AU - Nair, Parameswaran PY - 2017 DA - 2017/01/06 TI - Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy JO - Allergy, Asthma & Clinical Immunology SP - 2 VL - 13 IS - 1 AB - Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. SN - 1710-1492 UR - https://doi.org/10.1186/s13223-016-0174-5 DO - 10.1186/s13223-016-0174-5 ID - Mukherjee2017 ER -